The Alzheimer’s Drug Discovery Foundation has awarded a $900,000 grant to AgeneBio to support the initiation of a Phase 3 clinical trial for AGB101. AGB101 is an investigational therapeutic treatment for amnestic mild cognitive impairment (aMCI).
AGB101 is a proprietary formulation of low-dose levetiracetam, given to patients at about one-fifteenth of the dose most commonly prescribed for epilepsy. AGB101 targets hippocampal hyperactivity, a condition characteristic of the aMCI stage of Alzheimer’s disease. The Phase 3 trial will build on studies in both animal models and patients with aMCI that have demonstrated the importance of reducing hippocampal hyperactivity to restore the brain function necessary to maintain cognitive function and memory.
AgeneBio expects to initiate the AGB101 Phase 3 clinical program in the second half of 2015.
For more information visit AgeneBio.com.